Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ATYG 0.0008 now HUGE!! Change of control
Atlas’s redomicile from Florida to Delaware by means of a merger with and into a newly formed and wholly owned Delaware subsidiary corporation, Saxon Capital Group, Inc., formed for purposes of the merger with us in order to change the Company’s domicile and it will be a name change concurrently.
https://www.otcmarkets.com/filing/html?id=15985183&guid=Oi9-kaSFt2zKJth
$ATYG Looks like Dave cutler has completed some kind of merger with Saxon Capital Group Inc $SCGX $18.00 according to 8K this morning. https://twitter.com/DeepBlueEquity/status/1565699386298204160
https://www.otcmarkets.com/filing/html?id=15985183&guid=Oi9-kaSFt2zKJth
$AYTG 0.0006 is your next trip stock to0.01!! Merger out!! no RS mention!!
$ATYG WOW! 8k from last night
“by means of a merger with and into a newly formed and wholly owned Delaware subsidiary corporation, Saxon Capital Group, Inc.,”
Saxon Capital Group, inc. is trading at $18 with a market cap of $179m+
ATYG Market cap this morning 1.7m
https://www.otcmarkets.com/filing/html?id=15985183&guid=Oi9-kaSFt2zKJth
$ATYG WOW! 8k from last night
“by means of a merger with and into a newly formed and wholly owned Delaware subsidiary corporation, Saxon Capital Group, Inc.,”
Saxon Capital Group, inc. is trading at $18 with a market cap of $179m+
ATYG Market cap this morning 1.7m
https://www.otcmarkets.com/filing/html?id=15985183&guid=Oi9-kaSFt2zKJth
USRM finally!! Court Reports Favorable Judgment in California Stem Cell Case
Judge drops bombshell on FDA: https://ipscell.com/2022/08/judge-drops-a-bomb-on-fda-in-cell-surgical-network-stem-cell-clinic-case/
OTC DISCLOSURE & NEWS SERVICE
Court Reports Favorable Judgment in California Stem Cell Case
Press Release | 09/01/2022
SUNRISE, FL / ACCESSWIRE / September 1, 2022 / U.S. Stem Cell, Inc. (OTC:USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, is pleased to announce the long-awaited favorable ruling of the contemporaneous stem cell case against Cell Surgical Network, a stem cell company involved in a similar stem procedure as U.S. Stem Cell Inc. California federal judge, Jesus Bernal, has ruled in favor of Defendants California Stem Cell Treatment Center, Inc., Elliot B. Lander, M.D., Mark Berman, M.D., and Cell Surgical Network Corporation, in the United States v. California Stem Cell Treatment Centers case.
In the August 30th, 2022 judgment, Judge Bernal ruled that the Defendants' Stromal Vascular Fraction (SVF) Surgical Procedure nor its Expanded Mesenchymal Stem Cells (MSC) Procedure are "drugs" within the meaning of the Federal Food, Drug, and Cosmetic Act (FDCA). The SVF Procedure and Expanded MSC Procedure are not subject to the FDCA's adulteration and misbranding provisions. Additionally, the Defendants' SVF Procedure-but not the Expanded MSC Procedure-also qualifies for the Same Surgical Procedure Exception.
U.S. Stem Cell is gratified that judge Bernal of California ordered the case to proceed to trial and took the time to carefully review both the law and science. This is a major victory for the field of regenerative medicine and advocates of alternative stem cell-based treatments.
Since May 9th, 2018, U.S. Stem Cell, as one of the parties named, has been challenged by an injunctive action filed by the U.S. Department of Justice, at the request of the U.S. Food and Drug Administration (FDA). The suit alleged, among other matters, that the defendants manufactured SVF products from patient adipose (fat) tissue without first obtaining what the government alleged were necessary FDA approvals for a new drug. The Company has always maintained that stem cell treatments are medical procedures regulated by the respective State medical boards-and a patient's own stem cells are not drugs to be regulated by the federal government.
This new decision in the California case reinforces US Stem Cell Inc's position and is contrary to the ruling made on June 25th, 2019, where Florida-based (and now retired) federal court judge Ursula Ungaro ruled in favor of the government on summary judgment (and without giving the Company their day in court by holding a trial) and ruled that U.S. Stem Cell must stop most product sales, processes, and procedures. Judge Jesus Bernal instead allowed the complex matter to proceed to trial where Cell Surgical Network prevailed.
"Judge Bernal's ruling is a huge step forward in the field of regenerative medicine" states Mike Tomas, President & CEO. Adding "This ruling demonstrates our position that a patient's own stem cells are not a drug and provides us grounds to continue fighting to overturn U.S. Stem Cell's ruling."
Taking advantage of the different technologies housed within U.S. Stem Cell, the Company will take steps to rebrand and restructure to focus on the animal health division, including pet care regenerative medicine, geriatric care, and wellness through the subsidiary VetBiologics.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training, certification and stem cell products, as well as veterinary stem cell training and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
SOURCE: U.S. Stem Cell, Inc.
$RXMD Blasting on NEWS:
RXMD HUGE NEWS! Wednesday, August 31 2022 8:01 AM, EST NextPlat Invests $7 Million in Recapitalization of Progressive Care Inc. Accesswire "Press Releases"
Investment to Accelerate Progressive's Digital Healthcare Transformation and Launch of Global E-Commerce Platform for New Healthcare Products for Domestic and International Markets
COCONUT GROVE, FL / ACCESSWIRE / August 31, 2022 / NextPlat Corp (NASDAQ:NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider today announced that it has completed a strategic $7 million investment in Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare services and technology company ("Progressive Care").
Under the recapitalization plan, NextPlat Corp , its Executive Chairman and CEO, Charles M. Fernandez , and board member, Rodney Barreto , and certain other investors will invest an aggregate of $8.3 million into Progressive Care. In connection with the recapitalization, NextPlat will purchase 3,000 newly issued Units of Progressive Care valued at $6 million , with each Unit comprised of one share of Progressive Care's Series B Preferred Stock and one Warrant to purchase a share of Series B Preferred Stock. In addition, NextPlat Corp , Messrs. Fernandez and Barreto, and certain other investors will purchase $2.3 million of outstanding convertible debt from an existing holder. In connection with debt purchase, NextPlat Corp and the other purchasers agreed to a fixed conversion price of $0.02 per share of common stock and removal of the blocker. NextPlat Corp and the other purchasers also agreed to reduce the interest rate on the purchased debt from 10% to 5% per annum.
NextPlat's management team and select members of its Board of Directors will provide Progressive Care with their market-proven expertise in healthcare and digital technology including the development of new healthcare and lifestyle products to be sold via NextPlat's global e-commerce marketplaces. As part of this transaction, Mr. Fernandez will be appointed as Chairman of Progressive Care replacing Alan Jay Weisberg who will step down from his current positions to assume the new roles of Vice Chairman and CEO. Mr. Barreto will also be joining Progressive Care's board as Vice Chairman. Dawson James Securities Inc. ("Dawson") served as the placement agent for this transaction. Progressive Care intends to utilize a portion of the growth capital to further fund deployment of its digital platforms and the development and sale of new health, fitness, and beauty products.
Progressive Care Inc. is a Florida -based technology-centric healthcare organization. It provides prescription pharmaceuticals and contracted pharmacy services directly to consumers, long-term care facilities as well to 340B covered entities in underserved or vulnerable communities in 13 states. Progressive Care also has developed and provides extensive healthcare data management and analytics services in addition to providing virtual healthcare to customers. In 2021, Progressive Care reported annual revenues of approximately $40 million .
Over the past 30 years, Mr. Fernandez has successfully identified profitable start-up and dislocation opportunities, and built significant shareholder value, executing both private and public exits. Mr. Fernandez's expertise in technology and healthcare includes co-founding Lakeview Health Systems (acquired by a private equity firm for approximately $70 million ) and Continucare Corporation (acquired by Metropolitan Health Networks, Inc. for approximately $400 million ) where he served as chairman, president and CEO. He also served as an investor, director, and Chairman of the Audit Committee of IVAX Corporation for nearly a decade prior to its purchase by Teva Pharmaceuticals for $8.7 billion .
"Progressive Care has built a vibrant and rapidly growing healthcare services and technology company currently serving tens of thousands of customers who rely on its PharmcoRx platform and services every day. As a technology and healthcare entrepreneur, I see tremendous value in Progressive Care's capabilities which is why I am personally investing alongside of NextPlat . I believe we can leverage our expertise, industry know-how and global e-commerce platforms to accelerate their continued growth domestically as well as internationally. As long-term investors, we are committed to harnessing the power of digital technologies including Web3, to capitalize on the ongoing digital transformation of Progressive Care and the entire healthcare industry," said Charles M. Fernandez .
Alan Jay Weisberg commented, "Progressive Care has pursued a vision of being able to transform the healthcare industry by creating data-driven tools and technology. Charlie and the team at NextPlat have extensive knowledge and experience in utilizing digital technology and we believe will help Progressive Care build significant value for all stakeholders including patients, payors, practitioners, and investors. We are excited to have this team of industry leaders as our new long-term investors and partners, and look forward to working together advancing our vision for modern healthcare."
About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets for physical and digital assets. The Company intends to collaborate with businesses, optimizing their ability to sell their goods online, domestically, and internationally, and enabling customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications services division through its Global Telesat Communications Ltd and Orbital Satcom Corp business units that offer voice, data, tracking, and IoT services to customers worldwide through multiple global storefronts.
Progressive Care Inc. Progressive Care Inc. (OTCQB:RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.
RXMD HUGE NEWS! Wednesday, August 31 2022 8:01 AM, EST NextPlat Invests $7 Million in Recapitalization of Progressive Care Inc. Accesswire "Press Releases"
Investment to Accelerate Progressive's Digital Healthcare Transformation and Launch of Global E-Commerce Platform for New Healthcare Products for Domestic and International Markets
COCONUT GROVE, FL / ACCESSWIRE / August 31, 2022 / NextPlat Corp (NASDAQ:NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider today announced that it has completed a strategic $7 million investment in Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare services and technology company ("Progressive Care").
Under the recapitalization plan, NextPlat Corp , its Executive Chairman and CEO, Charles M. Fernandez , and board member, Rodney Barreto , and certain other investors will invest an aggregate of $8.3 million into Progressive Care. In connection with the recapitalization, NextPlat will purchase 3,000 newly issued Units of Progressive Care valued at $6 million , with each Unit comprised of one share of Progressive Care's Series B Preferred Stock and one Warrant to purchase a share of Series B Preferred Stock. In addition, NextPlat Corp , Messrs. Fernandez and Barreto, and certain other investors will purchase $2.3 million of outstanding convertible debt from an existing holder. In connection with debt purchase, NextPlat Corp and the other purchasers agreed to a fixed conversion price of $0.02 per share of common stock and removal of the blocker. NextPlat Corp and the other purchasers also agreed to reduce the interest rate on the purchased debt from 10% to 5% per annum.
NextPlat's management team and select members of its Board of Directors will provide Progressive Care with their market-proven expertise in healthcare and digital technology including the development of new healthcare and lifestyle products to be sold via NextPlat's global e-commerce marketplaces. As part of this transaction, Mr. Fernandez will be appointed as Chairman of Progressive Care replacing Alan Jay Weisberg who will step down from his current positions to assume the new roles of Vice Chairman and CEO. Mr. Barreto will also be joining Progressive Care's board as Vice Chairman. Dawson James Securities Inc. ("Dawson") served as the placement agent for this transaction. Progressive Care intends to utilize a portion of the growth capital to further fund deployment of its digital platforms and the development and sale of new health, fitness, and beauty products.
Progressive Care Inc. is a Florida -based technology-centric healthcare organization. It provides prescription pharmaceuticals and contracted pharmacy services directly to consumers, long-term care facilities as well to 340B covered entities in underserved or vulnerable communities in 13 states. Progressive Care also has developed and provides extensive healthcare data management and analytics services in addition to providing virtual healthcare to customers. In 2021, Progressive Care reported annual revenues of approximately $40 million .
Over the past 30 years, Mr. Fernandez has successfully identified profitable start-up and dislocation opportunities, and built significant shareholder value, executing both private and public exits. Mr. Fernandez's expertise in technology and healthcare includes co-founding Lakeview Health Systems (acquired by a private equity firm for approximately $70 million ) and Continucare Corporation (acquired by Metropolitan Health Networks, Inc. for approximately $400 million ) where he served as chairman, president and CEO. He also served as an investor, director, and Chairman of the Audit Committee of IVAX Corporation for nearly a decade prior to its purchase by Teva Pharmaceuticals for $8.7 billion .
"Progressive Care has built a vibrant and rapidly growing healthcare services and technology company currently serving tens of thousands of customers who rely on its PharmcoRx platform and services every day. As a technology and healthcare entrepreneur, I see tremendous value in Progressive Care's capabilities which is why I am personally investing alongside of NextPlat . I believe we can leverage our expertise, industry know-how and global e-commerce platforms to accelerate their continued growth domestically as well as internationally. As long-term investors, we are committed to harnessing the power of digital technologies including Web3, to capitalize on the ongoing digital transformation of Progressive Care and the entire healthcare industry," said Charles M. Fernandez .
Alan Jay Weisberg commented, "Progressive Care has pursued a vision of being able to transform the healthcare industry by creating data-driven tools and technology. Charlie and the team at NextPlat have extensive knowledge and experience in utilizing digital technology and we believe will help Progressive Care build significant value for all stakeholders including patients, payors, practitioners, and investors. We are excited to have this team of industry leaders as our new long-term investors and partners, and look forward to working together advancing our vision for modern healthcare."
About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets for physical and digital assets. The Company intends to collaborate with businesses, optimizing their ability to sell their goods online, domestically, and internationally, and enabling customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications services division through its Global Telesat Communications Ltd and Orbital Satcom Corp business units that offer voice, data, tracking, and IoT services to customers worldwide through multiple global storefronts.
Progressive Care Inc. Progressive Care Inc. (OTCQB:RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.
$RXMD NextPlat (NASDAQ stock $NXPL) Invests $7M in $RXMD
It’s massive news for OTC stock! https://twitter.com/NarutOTC_/status/1564978511479201792/photo/1
RMXD huge news unnoticed!!! 7m-investment
https://seekingalpha.com/news/3878883-nextplat-completes-7m-investment-in-progressive-care?utm_source=otcmarkets&utm_medium=referral
IMAGINE HPCO opens tomorrow @ $20.00!! what would happen to GGII????
Hempacco Co., Inc.
1,000,000
Shares of Common Stock
This is an initial public offering of our common stock. We are offering 1,000,000 shares of our common stock. The estimated initial public offering price is expected to be $6.00 per share.
Currently, there is no public market for our common stock. We have applied to list our common stock on the Nasdaq Capital Market, under the symbol "HPCO." We cannot guarantee that our common stock will be approved for listing on the Nasdaq Capital Market, and if our application is not approved, this offering cannot be completed.
After completion of this offering, public investors in the public offering will own approximately 4.3% of our outstanding shares of common stock, other investors will own approximately 15.7% of our outstanding shares of common stock, and approximately 79.9% of our outstanding common stock will be owned by Green Globe International, Inc. $GGII ,
HPCO GGII Hempacco Co., Inc. IPO tomorrow
priced @$6 79.9% owned by $GGII
1,000,000
Shares of Common Stock
This is an initial public offering of our common stock. We are offering 1,000,000 shares of our common stock. The estimated initial public offering price is expected to be $6.00 per share.
Currently, there is no public market for our common stock. We have applied to list our common stock on the Nasdaq Capital Market, under the symbol "HPCO." We cannot guarantee that our common stock will be approved for listing on the Nasdaq Capital Market, and if our application is not approved, this offering cannot be completed.
After completion of this offering, public investors in the public offering will own approximately 4.3% of our outstanding shares of common stock, other investors will own approximately 15.7% of our outstanding shares of common stock, and approximately 79.9% of our outstanding common stock will be owned by Green Globe International, Inc.,CO IPO
Hempacco Co., Inc.
1,000,000
Shares of Common Stock
This is an initial public offering of our common stock. We are offering 1,000,000 shares of our common stock. The estimated initial public offering price is expected to be $6.00 per share.
Currently, there is no public market for our common stock. We have applied to list our common stock on the Nasdaq Capital Market, under the symbol "HPCO." We cannot guarantee that our common stock will be approved for listing on the Nasdaq Capital Market, and if our application is not approved, this offering cannot be completed.
After completion of this offering, public investors in the public offering will own approximately 4.3% of our outstanding shares of common stock, other investors will own approximately 15.7% of our outstanding shares of common stock, and approximately 79.9% of our outstanding common stock will be owned by Green Globe International, Inc.,
$GGII added 0123 huge bidders Selling is over. - IPO of $HPCO tomorrow.
Watching for a bounce from this area.
GGII 0.0120 this is ready to bounce hard! ipo is tomorrow! 0.02+ eod!
GGII this can hit 0.02 by eod! WOW!!!
GGII can close at 0.0075!! massive buying!!!
This can hits 0.01 tomorrow early morning! trading thin! $GGII
BORK ask slapping!!
outstanding just increased!
291,809,224 (2022-08-18)
?? 305,655,378 (2022-08-22)
Difference: +4.7% (+13M)
dilution!
Nice! I wanted to know how they secured a $US 3 billion equity investment commitment from a Gulf Cooperation! what security does the company has to get this loan! 3 BILLION not 3 MILLION!!
anyone confirmed the"news" with CEO?
DVLP $60,000,000 assets anticipated LOI to acquire assets anticipated to provide sales in excess of $60,000,000 per year upon completion
per year upon completion
needs to hold 0.0014 or can see 0.0010 quickly! can people hold this over the weekend? can we trust the 3 BILLION PR???
DVLP 0.0055 LOI to acquire assets anticipated to provide sales in excess of $60,000,000 per year upon completion
TONR outstanding raised to 4,583,126,702 (2022-08-19)
Difference: +20.5% (+779M)
https://www.otcmarkets.com/stock/TONR/security
TONR outstanding raised to 4,583,126,702 (2022-08-19)
Difference: +20.5% (+779M)
DVLP massive PR! We are excited to announce we have executed an LOI to acquire assets anticipated to provide sales in excess of $60,000,000 per year upon completion. Definitive documents have been prepared and sent for review/signing.
https://www.otcmarkets.com/stock/DVLP/news/story?e&id=2300477
$DVLP HUGE Detailed PR. Looking at 97M Revs in first 3 acquisitions. Which lines up with their Roadmap and Projections. Possibly exceeding.
@OTC_DVLP
https://otcmarkets.com/stock/DVLP/news/story?e&id=2300477
PR looks fake!!!
TLIF 0.0460 starting WOW custodianship discharged! incoming RM!
could be 100%-500% mover from here!
haha hopefully people took advantage of this unexpected pop! lol
Thanks! It is funny how this 8-K hit CNGT and not EMGE!! The deal is between Regen Biowellness, Inc. and EMGE which is down (10%)! ?
Okay, so can you tell me wheres the connection with .Cannagistics Inc. on the 8K?
This is what I am saying!! where is the deal for Cannagistics Inc. CNGT?
So Regen Biowellness, Inc., the holder of 4,400,000 shares of Series F Preferred Voting Stock, sold all assets and certain liabilities of Regen Biowellness. to Emergent Health Corp. (“OTCPink “EMGE”)
The 4,400,000 shares of Series F Preferred Stock of the Registrant which represents voting control over the Registrant.
SO Regen Biowellness, Inc.(SELLER) has sold all assets now what is the DEAL with CNGT?
no mention of RS cancelation! Asset deal between Regen Biowellness, Inc.,and Emergent Health Corp. (“OTCPink “EMGE”)
WOW $YECO 0.565 up 123% should be $14 on this news!!! o/s 7 million
EV Biologics Launches Excyte with $100 million Valuation
Press Release | 08/15/2022
TAMPA, FL / ACCESSWIRE / August 15, 2022 / EV Biologics Corp, OTC Pink: YECO, today announced that it has launched Excyte, Inc., a wholly owned subsidiary, with $100 Million valuation.
https://storage.googleapis.com/accesswire/media/712022/EVBIOLOGO.jpg
Excyte has already raised $500,000 of its $2.5 million initial capitalization goal. This funding will initially provide scale-down biomanufacturing process development and important bioanalytical data to advance EV Biologics' ongoing nanotherapeutic development.
Funds allocated to comparative evaluation of small-scale automated bioreactor platforms will enable development of scalable biomanufacturing of stem cell-derived nanotherapeutics. The remainder of these funds will be allocated to analysis of the biomolecular composition and the biological activity of the composite secretome products and constituent vesicular and non-vesicular nanoparticle fractions produced by mesenchymal stem/stromal cell (MSC) banks already isolated and expanded by EV Biologics.
Excyte is founded on the idea that potent biotherapeutics and a deeper understanding of health, disease and aging can be obtained from living cells. Our mission is to further the understanding of the complex interactions between the multiplex of functional biomolecules that comprise cell-derived nanotherapeutics and the interconnected cellular pathways of biological systems in disease and aging. The Company will be focused on innovation in biomanufacturing, bioengineering, bioanalytics and machine learning toward a versatile platform for on-demand precision nanotherapeutic development for any clinical indication.
CEO, Daniel Mckinney, said "Our audacious goal is to unravel the complex mechanisms of stem cell therapy and apply this understanding to recreate defined regenerative therapeutics. Our innovative approach to longevity will use a multi-functional nanotherapeutic platform to deliver the right bioactive molecules to diseased, damaged, or aging cells to restore health, combat aging and provide a longer health span. Simply put, our goal is the ‘Fountain of Youth'".
Excyte joins a narrow field of notable biotechnology ventures focused on longevity and extending the human health span, such as Altos Labs (https://www.economist.com/science-and-technology/a-3bn-bet-on-finding-the-fountain-of-youth/21807244) and Retro Biosciences (https://www.biospace.com/article/retro-biosciences-launches-with-180-million-to-increase-healthy-human-lifespan-by-10-years-/?s=89).
Excyte will take a very pragmatic approach to innovation in the longevity space with accelerated development of products and technologies that can be further commercialized in parallel with its primary development pathway. The Company will use virtual infrastructure and collaboration with best-in-class commercial partners to execute its biotechnology innovations and minimize capital requirements and operating costs. Intellectual property, patents, proprietary process and product development will be held by Excyte in support of EV Biologics.
About EV Biologics
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, developing a range of nanotherapeutics to substantially enhance the intrinsic bioactivity of stem and progenitor cell-derived nanoparticles. The Company is also developing biomanufacturing, bioinformatic and bioengineering innovations to optimize production of nanoparticle therapeutics and biologics. These versatile therapeutic platforms will enable generation of nanotherapeutics targeting a broad range of regenerative medicine and longevity applications.
About Excyte
Excyte, a wholly owned subsidiary of EV Biologics, Inc., is founded on the idea that potent biotherapeutics and a deeper understanding of health, disease and aging can be obtained from living cells. Our mission is to further the understanding of the complex interactions between the multiplex of functional biomolecules that comprise cell-derived nanotherapeutics and the interconnected cellular pathways of biological systems in disease and aging. The Company is focused on innovation in biomanufacturing, bioengineering, bioanalytics and machine learning in support of a versatile platform for on-demand precision nanotherapeutic development for any clinical indication. Our innovative approach to longevity will use a multi-functional nanotherapeutic platform to deliver the right bioactive molecules to diseased, damaged or aging cells to restore health, combat aging and provide a longer health span.
$YECO $0.4111 with Today's news should be $14!!!
market cap is less $2 now!!!!??
EV Biologics Launches Excyte with $100 million Valuation
Press Release | 08/15/2022
TAMPA, FL / ACCESSWIRE / August 15, 2022 / EV Biologics Corp, OTC Pink: YECO, today announced that it has launched Excyte, Inc., a wholly owned subsidiary, with $100 Million valuation.
https://storage.googleapis.com/accesswire/media/712022/EVBIOLOGO.jpg
Excyte has already raised $500,000 of its $2.5 million initial capitalization goal. This funding will initially provide scale-down biomanufacturing process development and important bioanalytical data to advance EV Biologics' ongoing nanotherapeutic development.
Funds allocated to comparative evaluation of small-scale automated bioreactor platforms will enable development of scalable biomanufacturing of stem cell-derived nanotherapeutics. The remainder of these funds will be allocated to analysis of the biomolecular composition and the biological activity of the composite secretome products and constituent vesicular and non-vesicular nanoparticle fractions produced by mesenchymal stem/stromal cell (MSC) banks already isolated and expanded by EV Biologics.
Excyte is founded on the idea that potent biotherapeutics and a deeper understanding of health, disease and aging can be obtained from living cells. Our mission is to further the understanding of the complex interactions between the multiplex of functional biomolecules that comprise cell-derived nanotherapeutics and the interconnected cellular pathways of biological systems in disease and aging. The Company will be focused on innovation in biomanufacturing, bioengineering, bioanalytics and machine learning toward a versatile platform for on-demand precision nanotherapeutic development for any clinical indication.
CEO, Daniel Mckinney, said "Our audacious goal is to unravel the complex mechanisms of stem cell therapy and apply this understanding to recreate defined regenerative therapeutics. Our innovative approach to longevity will use a multi-functional nanotherapeutic platform to deliver the right bioactive molecules to diseased, damaged, or aging cells to restore health, combat aging and provide a longer health span. Simply put, our goal is the ‘Fountain of Youth'".
Excyte joins a narrow field of notable biotechnology ventures focused on longevity and extending the human health span, such as Altos Labs (https://www.economist.com/science-and-technology/a-3bn-bet-on-finding-the-fountain-of-youth/21807244) and Retro Biosciences (https://www.biospace.com/article/retro-biosciences-launches-with-180-million-to-increase-healthy-human-lifespan-by-10-years-/?s=89).
Excyte will take a very pragmatic approach to innovation in the longevity space with accelerated development of products and technologies that can be further commercialized in parallel with its primary development pathway. The Company will use virtual infrastructure and collaboration with best-in-class commercial partners to execute its biotechnology innovations and minimize capital requirements and operating costs. Intellectual property, patents, proprietary process and product development will be held by Excyte in support of EV Biologics.
About EV Biologics
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, developing a range of nanotherapeutics to substantially enhance the intrinsic bioactivity of stem and progenitor cell-derived nanoparticles. The Company is also developing biomanufacturing, bioinformatic and bioengineering innovations to optimize production of nanoparticle therapeutics and biologics. These versatile therapeutic platforms will enable generation of nanotherapeutics targeting a broad range of regenerative medicine and longevity applications.
About Excyte
Excyte, a wholly owned subsidiary of EV Biologics, Inc., is founded on the idea that potent biotherapeutics and a deeper understanding of health, disease and aging can be obtained from living cells. Our mission is to further the understanding of the complex interactions between the multiplex of functional biomolecules that comprise cell-derived nanotherapeutics and the interconnected cellular pathways of biological systems in disease and aging. The Company is focused on innovation in biomanufacturing, bioengineering, bioanalytics and machine learning in support of a versatile platform for on-demand precision nanotherapeutic development for any clinical indication. Our innovative approach to longevity will use a multi-functional nanotherapeutic platform to deliver the right bioactive molecules to diseased, damaged or aging cells to restore health, combat aging and provide a longer health span.
YECO EV Biologics Launches Excyte with $100 million Valuation
Press Release | 08/15/2022
TAMPA, FL / ACCESSWIRE / August 15, 2022 / EV Biologics Corp, OTC Pink: YECO, today announced that it has launched Excyte, Inc., a wholly owned subsidiary, with $100 Million valuation.
https://storage.googleapis.com/accesswire/media/712022/EVBIOLOGO.jpg
Excyte has already raised $500,000 of its $2.5 million initial capitalization goal. This funding will initially provide scale-down biomanufacturing process development and important bioanalytical data to advance EV Biologics' ongoing nanotherapeutic development.
Funds allocated to comparative evaluation of small-scale automated bioreactor platforms will enable development of scalable biomanufacturing of stem cell-derived nanotherapeutics. The remainder of these funds will be allocated to analysis of the biomolecular composition and the biological activity of the composite secretome products and constituent vesicular and non-vesicular nanoparticle fractions produced by mesenchymal stem/stromal cell (MSC) banks already isolated and expanded by EV Biologics.
Excyte is founded on the idea that potent biotherapeutics and a deeper understanding of health, disease and aging can be obtained from living cells. Our mission is to further the understanding of the complex interactions between the multiplex of functional biomolecules that comprise cell-derived nanotherapeutics and the interconnected cellular pathways of biological systems in disease and aging. The Company will be focused on innovation in biomanufacturing, bioengineering, bioanalytics and machine learning toward a versatile platform for on-demand precision nanotherapeutic development for any clinical indication.
CEO, Daniel Mckinney, said "Our audacious goal is to unravel the complex mechanisms of stem cell therapy and apply this understanding to recreate defined regenerative therapeutics. Our innovative approach to longevity will use a multi-functional nanotherapeutic platform to deliver the right bioactive molecules to diseased, damaged, or aging cells to restore health, combat aging and provide a longer health span. Simply put, our goal is the ‘Fountain of Youth'".
Excyte joins a narrow field of notable biotechnology ventures focused on longevity and extending the human health span, such as Altos Labs (https://www.economist.com/science-and-technology/a-3bn-bet-on-finding-the-fountain-of-youth/21807244) and Retro Biosciences (https://www.biospace.com/article/retro-biosciences-launches-with-180-million-to-increase-healthy-human-lifespan-by-10-years-/?s=89).
Excyte will take a very pragmatic approach to innovation in the longevity space with accelerated development of products and technologies that can be further commercialized in parallel with its primary development pathway. The Company will use virtual infrastructure and collaboration with best-in-class commercial partners to execute its biotechnology innovations and minimize capital requirements and operating costs. Intellectual property, patents, proprietary process and product development will be held by Excyte in support of EV Biologics.
About EV Biologics
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, developing a range of nanotherapeutics to substantially enhance the intrinsic bioactivity of stem and progenitor cell-derived nanoparticles. The Company is also developing biomanufacturing, bioinformatic and bioengineering innovations to optimize production of nanoparticle therapeutics and biologics. These versatile therapeutic platforms will enable generation of nanotherapeutics targeting a broad range of regenerative medicine and longevity applications.
About Excyte
Excyte, a wholly owned subsidiary of EV Biologics, Inc., is founded on the idea that potent biotherapeutics and a deeper understanding of health, disease and aging can be obtained from living cells. Our mission is to further the understanding of the complex interactions between the multiplex of functional biomolecules that comprise cell-derived nanotherapeutics and the interconnected cellular pathways of biological systems in disease and aging. The Company is focused on innovation in biomanufacturing, bioengineering, bioanalytics and machine learning in support of a versatile platform for on-demand precision nanotherapeutic development for any clinical indication. Our innovative approach to longevity will use a multi-functional nanotherapeutic platform to deliver the right bioactive molecules to diseased, damaged or aging cells to restore health, combat aging and provide a longer health span.